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Management of depression for people with cancer 
(SMaRT oncology 1): a randomised trial
Vanessa Strong, Rachel Waters, Carina Hibberd, Gordon Murray, Lucy Wall, Jane Walker, Gillian McHugh, Andrew Walker, Michael Sharpe
Summary
Background Major depressive disorder severely impairs the quality of life of patients with medical disorders such as 
cancer, but evidence to guide its management is scarce. We aimed to assess the eﬃ  cacy and cost of a nurse-delivered 
complex intervention that was designed to treat major depressive disorder in patients who have cancer.
Methods We did a randomised trial in a regional cancer centre in Scotland, UK. 200 outpatients who had cancer with 
a prognosis of greater than 6 months and major depressive disorder (identiﬁ ed by screening) were eligible and agreed 
to take part. Their mean age was 56·6 (SD 11·9) years, and 141 (71%) were women. We randomly assigned 99 of these 
participants to usual care, and 101 to usual care plus the intervention, with minimisation for sex, age, diagnosis, and 
extent of disease. The intervention was delivered by a cancer nurse at the centre over an average of seven sessions. 
The primary outcome was the diﬀ erence in mean score on the self-reported Symptom Checklist-20 depression scale 
(range 0 to 4) at 3 months after randomisation. Analysis was by intention to treat. This trial is registered as 
ISRCTN84767225.
Findings Primary outcome data were missing for four patients. For 196 patients for whom we had data at 3 months, 
the adjusted diﬀ erence in mean Symptom Checklist-20 depression score, between those who received the intervention 
and those who did not, was 0·34 (95% CI 0·13–0·55). This treatment eﬀ ect was sustained at 6 and 12 months. The 
intervention also improved anxiety and fatigue but not pain or physical functioning. It cost an additional £5278 
(US$10 556) per quality-adjusted life-year gained.
Interpretation The intervention—Depression Care for People with Cancer—oﬀ ers a model for the management of 
major depressive disorder in patients with cancer and other medical disorders who are attending specialist medical 
services that is feasible, acceptable, and potentially cost eﬀ ective.
Funding Cancer Research UK.
Introduction
Depression is rapidly becoming one of the most 
pressing public health challenges in the world.1 A 
2007 WHO survey reported that depression had an 
especially large eﬀ ect on health when it was comorbid 
with a chronic medical disorder.2 Despite its importance, 
management of depression in patients with medical 
disorders has been shown to be inadequate—with 
failure to diagnose depression, to provide evidence-based 
treatment, or to actively follow up treatment to ensure 
that a response has been achieved.3–5 If we are to 
improve outcomes for patients who have depression 
that is comorbid with a medical disorder, we need a 
system of care that addresses all these failings, is 
acceptable to medical patients, and is feasible and 
cost eﬀ ective to deliver.
We developed a system of care that combines systematic 
screening with a complex intervention, and integrates 
management of depression into patients’ cancer care. 
Screening is needed to identify patients with major 
depressive disorder,5 but on its own does not improve 
patients’ outcomes.6 The complex inter vention,7 called 
Depression Care for People with Cancer,8 was based on 
an intervention for the manage ment of depression in 
primary care (known as collaborative care),9,10 and was 
designed to be delivered by a nurse to patients who 
attended a specialist cancer centre. 
We aimed to investigate whether adding this inter-
vention to usual care could achieve a greater reduction in 
depressive symptoms at 3 months than could usual care 
alone, and whether this would be sustained at 6 and 
12 months. This is the ﬁ rst in a series of trials of complex 
interventions for various symptoms in medical patients: 
Symptom Management Research Trials (SMaRT).
Methods
Study design and patients
Between October, 2003, and December, 2005, we used a 
screening system to identify patients with major depressive 
disorder. We screened patients attending clinics for breast, 
colorectal, gynaecological, genitourinary, haematological, 
lung, and mixed cancers in a regional tertiary National 
Health Service (NHS) cancer centre that served a 
geographically deﬁ ned population of 1·5 million people in 
the southeast of Scotland, UK. The screening system had 
two stages. First, patients completed the Hospital Anxiety 
and Depression Scale questionnaire, on a touch-screen 
computer.11 Second, patients who had a score of 15 or more 
were interviewed by telephone12 with use of the major 
depression section of the Structured Clinical Interview for 
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the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV).13 Patients who had major depressive disorder, 
according to these criteria, were invited to be assessed for 
eligibility to participate in the trial. Assessment was by 
initial telephone screen, then a face-to-face interview.
Eligible patients had to have: a cancer prognosis of at 
least 6 months (to ensure that they could complete the 
trial); major depressive disorder of at least a month’s 
duration that was not associated with major changes in 
the patient’s cancer or its management (to ensure that 
we did not include patients with transient adjustment 
disorders); and a minimum severity of major depressive 
disorder, deﬁ ned by a score on the Symptom Checklist-20 
(SCL-20) depression scale14 of at least 1·75 (higher than 
the 1·5 which is usually regarded as equivalent to major 
depressive disorder, to allow for physical symptoms of 
cancer).
We excluded patients who were unlikely to be able to 
adhere to the intervention: reasons included major 
communication diﬃ  culties such as severe deafness or 
dementia, inability to attend the cancer centre, con-
current intensive anticancer treatment such as frequent 
chemotherapy or radiotherapy, or another poorly 
controlled medical disorder such as epilepsy that 
dominated their care. We also excluded those who were 
receiving, or were judged to need, specialist psychiatric 
care (eg, chronic major depressive disorder of more 
than 2 years’ duration, severe substance or alcohol 
misuse, comorbid severe psychiatric disorder such as 
psychosis, or risk of suicide). Our justiﬁ cation was that 
we aimed to supplement the care of depression in the 
cancer centre, not to treat problems requiring specialist 
psychiatric care, which is freely available in the UK.
We recorded written informed consent from all eligible 
patients who agreed to take part. We then randomly 
assigned these patients to either usual care alone or 
usual care supplemented with the intervention. After 
baseline data were gathered, the assessing nurse faxed 
details to the trial unit. A computer programme was 
used to allocate patients to the two groups, with 
minimisation for sex, age (≤39, 40–79, and ≥80 years), 
primary cancer site (breast, colorectal, gynaecological, 
and other cancer), and extent of disease (disease-free 
after initial treatment, local disease, and metastatic 
disease). The aim was to minimise speciﬁ c diﬀ erences 
in known or suspected determinants of outcome between 
the groups. The nurse was informed of the assignment 
for each patient by telephone. The local research ethics 
committee approved the trial protocol.
Procedures
All patients in the trial received usual care. Every patient 
in the UK has a primary-care doctor (referred to as a 
general practitioner). Patients who attend specialist 
medical services can receive treatment for depression 
either from their primary-care doctor or from a hospital 
specialist. Both primary-care and specialist NHS medical 
services are free at the point of delivery. We informed 
each patient’s primary-care doctor and oncologist of 
their diagnosis of major depressive disorder and 
provided advice on choice of antidepressant drug if 
requested.
In addition to usual care, patients in the intervention 
group were oﬀ ered a maximum of 10 one-to-one sessions 
over 3 months, preferably in person at the cancer centre 
but occasionally by telephone or at patients’ homes if 
they were unable to attend the centre. The content of the 
intervention, Depression Care for People with Cancer, 
comprised education about depression and its treatment 
(including antidepressant medication); problem-solving 
treatment15 to teach the patients coping strategies 
designed to overcome feelings of helplessness; and com-
munication about management of major depressive 
disorder with each patient’s oncologist and primary-care 
doctor. For 3 months after the treatment sessions 
progress was monitored by monthly telephone calls. This 
monitoring used the nine-item Patient Health 
Questionnaire (PHQ-9)16 to assess the severity of depres-
sion. We oﬀ ered one or two additional sessions to patients 
who had increasing PHQ-9 scores.
Each 45 min treatment session was delivered by one of 
three cancer nurses, who followed a detailed manual 
(available from the corresponding author). All sessions 
were video-recorded, and 10% of sessions were randomly 
selected to be independently assessed for their adherence 
to the treatment manual. No further intervention was 
given after 6 months.
The nurses (who had experience equivalent to that of a 
charge nurse) had no previous experience of psychiatry, 
and were trained to deliver the intervention using written 
materials, tutorials, and supervised practice over at least 
3 months. Patients were allocated to nurses on the basis 
of the nurses’ workloads. A psychiatrist reviewed patients’ 
progress with the nurses every week. Nurses presented 
each patient’s scores on the Patient Health Questionnaire, 
their antidepressant dose, and their progress with 
problem-solving treatment. The patient’s management 
was then brieﬂ y discussed. If necessary, video recordings 
of sessions were reviewed.
Primary-care doctors prescribed all antidepressant 
medication. If the patient decided, during discussions 
with the nurse, to start or change antidepressant medi-
cation, they were encouraged to contact their primary-
care doctor for this purpose. The patient’s doctor was 
then contacted by the nurse (by fax or telephone) before 
their appointment to provide information about the 
patient and oﬀ er advice from a study psychiatrist.
Outcome measures
The primary outcome measure was the diﬀ erence in 
depressive symptoms, as self-reported by patients with 
the SCL-20 questionnaire, at 3 months after each patient 
was randomly assigned. The SCL-20 depression score, 
which is derived from the SCL-90 scale,14 is a valid and 
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reliable self-reported measure.17 The score is the mean of 
ratings for 20 items, and ranges from zero to four. 
Questionnaires were mailed to patients, and returned by 
mail. Data were collated at the cancer centre. Telephone 
interviews were used to obtain any data that were missing 
from responses to the questionnaire, to assess if a patient 
still had a diagnosis of major depressive disorder, and to 
record health-care use.
99 assigned to usual care
200 randomly assigned  
97 analysed for primary endpoint at 3 months 
0 lost to follow-up  
101 assigned to usual care plus the intervention 
99 analysed for primary endpoint at 3 months 
326 did not meet inclusion criteria*
         105 did not meet criteria
                  26 with expected survival of less than 6 months
                  10 with major depressive disorder for less than 1 month
                  69 with a SCL-20 depression score <1·75
            75 were unlikely to adhere to the intervention
                   19 with severe substance or alcohol abuse
                     5 with major communication diﬃculties
                  39 unable to attend the cancer centre
                     4 on intensive anti-cancer treatment
                     8 with another poorly controlled disease
         167 needed specialist psychiatric care
                  72 with chronic major depression for more than 2 years
                  16 with comorbid severe psychiatric disorder
                  33 with suicide risk
                  46 with current psychological or psychiatric treatment
134 refused to participate
         129 declined to be assessed for eligibility
              5 refused after being interviewed  
1 refused to provide outcome data
3 missing data because lost to follow-up
    2 died
    1 emigrated
11 lost to follow-up by 12 months
      7 died
            2 refused to participate
      2 could not be contacted 
17 lost to follow-up by 12 months
      12 died
        3 withdrew
        2 could not be contacted 
98 analysed up to 12 months
         4 with data at baseline and 3 months’ follow-up
          1 with data at baseline and 6 months’ follow-up
         6 with data at baseline, 3, and 6 months’ follow-up
         2 with data at baseline, 3, and 12 months’ follow-up
      85 with data at all timepoints
99 analysed up to 12 months
         6 with data at baseline and 3 months’ follow-up
       11 with data at baseline, 3, and 6 months’ follow-up
         2 with data at baseline, 3, and 12 months’ follow-up 
      80 with data at all timepoints
8153 patients with cancer screened by computer
           questionnaire and telephone interview for 
           major depressive disorder 
660 patients with major depressive disorder
          screened for eligibility  
7493 patients did not have major depressive disorder
Figure 1: Trial proﬁ le
*Some patients had more than one reason for exclusion.
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Secondary outcomes included response to treatment, 
which was deﬁ ned as a 50% reduction in the SCL-20 
depression score from baseline, and remission, which 
was deﬁ ned as an SCL-20 score of less than 0·75 
(compared with the 0·5 used in primary-care trials,17 to 
allow for cancer-related somatic symptoms). We also 
measured the SCL-20 depression score at 6 and 
12 months’ follow-up to assess the eﬀ ect of the inter-
vention over time. Persistence of a diagnosis of major 
depressive disorder was assessed, by interviewers who 
were unaware of treatment allocation, using the major 
depression section of the Structured Clinical Interview 
for DSM-IV.13 These interviews were by telephone—a 
method which has been shown to have good agreement 
with face-to-face interviews.18 Telephone interviewers did 
not attempt to judge whether symptoms were related to 
cancer; but used the so-called inclusive approach to 
diagnosis. To compensate for possible bias caused by the 
interviewers discovering treatment allocations during 
interviews, all the interviews were audio-recorded and 
edited to remove such information. An independent 
investigator reassessed these recordings; these reassess-
ments were used in the analysis.
We measured anxiety with a ten-item subscale of the 
SCL-90 questionnaire14 (which is scored in the same way 
as the depression scale); pain, fatigue, and physical 
functioning with the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ C30);19 and quality of life for the economic 
analysis with the Euroqol-5D questionnaire.20 This 
quality-of-life scale assesses mobility, self-care, usual 
activities, pain or discomfort, and depression or anxiety, 
on a scale from one (representing no problems) to three 
(representing major problems).
At 3 and 6 months, all patients recorded their number 
of visits to primary-care services; any use of antidepressant 
drugs, with doses; and any contact with community 
cancer-support services or specialist mental-health 
services. Therapeutic doses were predeﬁ ned (webtable). 
At 6 months, patients rated the quality of care received 
for their depression on a simple ﬁ ve-point scale from 
poor to excellent. For patients in the intervention group, 
the nurses who delivered the treatment sessions recorded 
their number and duration, and the amount of time with 
the supervising psychiatrist. We deﬁ ned serious adverse 
events as death from any cause and admission to hospital 
for depression. We monitored serious adverse events by 
patient report and review of case notes.
Statistical analysis
We planned a sample size of 200 patients, which would 
provide 80% power, at the 5% signiﬁ cance level, to ﬁ nd a 
clinically signiﬁ cant diﬀ erence in mean SCL-20 
depression scores of 0·21 (assuming a standard deviation 
of 0·5) and allowed for 5% loss to follow-up.21 The 
primary endpoint was the diﬀ erence in the mean SCL-20 
total score at 3 months. We did all analyses on an 
intention-to-treat basis, and included all randomised 
patients for whom outcome data were available.
We did analysis of covariance with the 3 month SCL-20 
depression score as the dependent variable, adjusted for 
baseline SCL-20 score and minimisation variables. The 
standardised eﬀ ect size was calculated by dividing the 
eﬀ ect size by the standard deviation, pooled across the 
two groups. No covariate data were missing. To account 
for missing outcome data, we did a sensitivity analysis 
on the conservative assumption of no change from 
baseline. To assess the stability of the treatment eﬀ ect, 
we ﬁ tted a mixed model for SCL-20 depression scores 
at 3, 6, and 12 months, adjusted for baseline SCL-20 and 
minimisation variables. We analysed 197 patients for 
whom we had an SCL-20 score at any of these times. 
The model treated time as a ﬁ xed categorical eﬀ ect, 
allowing for non-linear trends; we used a general 
covariance structure, since it substantially improved the 
log likelihood when compared with compound 
symmetry (p=0·06). We did three sensitivity analyses, 
checking the ﬁ t of the model against (1) single timepoint 
analyses, (2) a linear random coeﬃ  ecient model, and (3) 
data collected in speciﬁ ed time windows.  None of these 
aﬀ ected our results.
Binary secondary outcomes were analysed with logistic 
regression, adjusted for baseline SCL-20 depression 
score and minimisation variables. Continuous secondary 
outcome variables were analysed with analysis of 
covariance, with 3 month scores as the dependent 
variable adjusted for the baseline outcome and mini-
misation variables. Statistical signiﬁ cance was chosen as 
p<0·01 for all secondary outcomes to allow for the 
multiple testing. For partly complete data, we handled 
missing items according to the scale-speciﬁ c scoring 
manuals. We used EQ-5D scores to generate quality-
adjusted life-years,22 to adjust the time spent during the 
follow-up period according to quality of life.
We only gathered data on costs for up to 6 months, 
since this was the period over which the intervention 
was given. The costs of all treatments except cancer 
treatment in hospital were assessed (since changes in 
cancer treatment were not expected during this period). 
The costs of the intervention (treatment sessions, 
adminis tration and supervision time, follow-up 
telephone calls, and psychiatrist time) and costs of 
health-care contacts in usual care (eg, visits to 
primary-care doctor) were calculated by combining the 
data on contacts with established unit-cost information.23 
We obtained prices of antidepressant drugs from the 
2006 British National Formulary.24 We then calculated 
the incremental cost per quality-adjusted life-year as the 
average excess cost of the intervention divided by the 
average quality-adjusted life-year gain (of the intervention 
compared with usual care alone). Costs of training and 
screening to detect cases were not included. No 
discounting was used. We analysed all data with SAS 
software (version 9.1).
See Online for webtable
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Role of the funding source
The funder of this study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study, and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Figure 1 shows that, of the 660 patients with major 
depressive disorder whom we identiﬁ ed, 326 were not 
eligible for the trial and 134 patients did not agree to 
participate. Of the 83 who gave a speciﬁ c reason for 
refusal, most reported scepticism about whether the 
intervention would help them. Those who participated 
and those who declined did not diﬀ er in their 
demographic or cancer characteristics (data not shown). 
200 patients were enrolled and randomly assigned; 
99 to usual care, and 101 to usual care plus the 
intervention. Table 1 shows the demographic and 
clinical characteristics of patients at their entry to the 
trial.
Of the 101 patients in the group who had usual care 
plus the intervention, three did not attend any of their 
one-to-one sessions and the remainder had a mean of 
seven sessions (range two to ten). Most of the sessions 
were at the cancer centre, but six (6%) were by telephone 
and ﬁ ve (5%) were in patients’ homes. Nurses gave a total 
of eight additional booster sessions between 3 and 
6 months to six patients who had worsening PHQ-9 
depression scores. Independent assessment of video 
recordings of 14% of the sessions showed that 
89 (96%) were consistent with the treatment manual. 
At baseline, similar numbers in each group were taking 
therapeutic doses of antidepressant drugs: 17 (17%) in the 
intervention group and 20 (20%) in the usual care group. 
By 3 months, 68 (69%) in the intervention group were 
taking a therapeutic dose, compared with only 42 (42%) 
of those given usual care alone (p=0·0002). This diﬀ er-
ence persisted at 6 months (62 [65%] vs 32 [34%]; 
p<0·0001).
In the ﬁ rst 3 months, patients in the intervention group 
had a mean of 2·0 (SD 2·0) visits to the primary-care 
doctor, compared with 1·7 (2·3) in the usual care group; 
in the second 3 months they made 1·2 (1·8) and 
1·0 (1·6) visits, respectively. Very few primary-care 
doctors asked study psychiatrists for advice on pres-
cription of antidepressants. Only 22 (11%) of patients 
were seen by mental-health specialists (such as 
psychiatrists, psychologists, or psychiatric nurses) during 
the ﬁ rst 6 months of the trial (nine in the intervention 
group and 13 in the usual care group).
Of the 200 who were randomly assigned, we analysed 
the primary outcome in the 196 patients for whom data 
were available at 3 months (ﬁ gure 1). Figure 2 shows that 
depression scores on the SCL-20 fell between baseline 
and 3 months in both groups, but fell more in the 
intervention group. The median baseline depression 
score was 2·35 (IQR 2·05–2·75) in the intervention 
group and 2·25 (1·95–2·75) in those given usual care 
alone; after 3 months, this fell to 1·20 (0·70–1·70) and 
1·55 (0·90–2·00), respectively. The mean reduction at 
Usual care 
group (N=99)
Usual care plus 
intervention group 
(N=101)
Age 56·6 (12·3) 56·6 (11·4)
<40 years 11 (11%) 10 (10%)
40–79 years 84 (85%) 89 (88%)
≥80 years 4 (4%) 2 (2%)
Sex
Male 28 (28%) 31 (31%)
Female 71 (72%) 70 (69%)
Primary cancer
Breast 44 (44%) 43 (43%)
Gynaecological 15 (15%) 16 (16%)
Colorectal 6 (6%) 7 (7%)
Other 34 (34%)* 35 (35%)†
Time since most recent cancer 
diagnosis‡ (months) 
20·0 (9·1–44·7) 13·0 (5·5–33·7)
Extent of disease
Disease-free 67 (68%) 65 (64%)
Local disease 22 (22%) 20 (20%)
Metastatic disease 10 (10%) 16 (16%)
Cancer treatment stage
Pretreatment 2 (2%) 0 
Under investigation 15 (15%) 4 (4%)
Active treatment 15 (15%) 19 (19%)
Post-treatment assessment 3 (3%) 2 (2%)
Monitoring 64 (65%) 76 (75%)
Cancer treatment
No active treatment 84 (85%) 82 (81%)
Chemotherapy 10 (10%) 9 (9%)
Radiotherapy 3 (3%) 7 (7%)
Both 2 (2%) 3 (3%)
Duration of current depressive 
episode (months) 
6 (3–12) 8 (4–16)
Antidepressant use at trial entry
At any dose 29 (29%) 25 (25%)
At therapeutic dose 20 (20%) 17 (17%)
Symptoms
Depression score§ (0–4) 2·25 (1·95–2·75) 2·35 (2·05–2·75)
Anxiety score¶ (0–4) 1·3 (0·7–2·1) 1·5 (0·9–2·2)
Pain score|| (0–100) 33 (17–67) 33 (17–67)
Fatigue score|| (0–100) 56 (44–78) 56 (44–78)
Physical functioning|| (0–100) 73 (53–87) 67 (53–87)
Data are number (%), mean (SD), or median (interquartile range). *Other primary 
cancers included 9 prostate, 10 haematological, 8 testicular, 2 urinary tract, 
1 lung, 2 skin, and 2 sarcoma. †Other primary cancers included 10 prostate, 
10 haematological, 8 testicular, 3 urinary tract, 3 lung, and 1 skin. ‡Diagnosis of 
cancer, of recurrence, or of metastases. §Symptom Checklist-20.14 ¶Symptom 
Checklist-10.14 ||European Organisation for Research and Treatment of Cancer 
quality of life questionnaire.19
Table 1: Baseline characteristics
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3 months in the intervention group compared with usual 
care, adjusted for baseline SCL-20 score and minimisation 
variables, was 0·34 (95% CI 0·13–0·55; p=0·002). The 
standardised mean diﬀ erence, or eﬀ ect size, was 0·43 
(0·16–0·71). No interactions of minimisation factors 
(including cancer type) with the intervention were 
signiﬁ cant at the 5% level.
For the four patients for whom outcome data at 
3 months were missing, we used their baseline SCL-20 
depression scores as the 3 month scores. When this was 
done the diﬀ erence between groups was 0·30 (95% CI 
0·08–0·51) and remained signiﬁ cant (p=0·007).
Figure 3 shows the unadjusted SCL-20 depression 
scores at each timepoint. Depression scores for patients 
in the intervention group remained lower than scores in 
patients given usual care alone at both 6 and at 12 months 
after randomisation (at 6 months, they were 1·03 
[SD 0·79] vs 1·51 [0·81]; and at 12 months, 1·12 [0·89] and 
1·43 [0·94]).  
In the mixed model the adjusted mean diﬀ erence 
between SCL-20 depression scores in the group was 
largest at 6 months (−0·59, 95% CI −0·81 to −0·37). 
Although the diﬀ erence was less at 12 months (−0·42, 
−0·67 to −0·17) it was still larger than at 3 months (−0·34, 
−0·55 to −0·12).
Secondary outcomes are shown in table 2. The SCL-20 
depression score fell by at least 50% between baseline 
and 3 months for 51 (53%) patients in the intervention 
group, compared with 34 (34%) of those given usual care 
alone (p=0·008). The proportion who met our predeﬁ ned 
criterion for remission—an SCL-20 score of less 
than 0·75—was 15% greater with the intervention than 
without. If we deﬁ ned remission as an SCL-20 score of 
less than 0·5, as did previous non-cancer trials, 7% more 
patients in the intervention group had this result 
(OR 2·8, 95% CI 1·1–7·5, p=0·04). The eﬀ ect of the 
intervention was also evident in the proportion of 
patients who no longer met criteria for major depression 
on the Structured Clinical Interview for DSM-IV after 
3 months. Patients in the intervention group had a 
greater reduction in anxiety and in fatigue than did those 
given usual care alone, but not in pain or physical 
functioning at 3 months. These ﬁ ndings were similar at 
6 months (data not shown). At 6 months, 68 (79%) of the 
86 patients in the intervention group for whom we had 
data rated their care as very good or excellent.
The gain in quality of life associated with the intervention 
over the ﬁ rst 6 months was 0·063 quality-adjusted 
life-years (95% CI 0·032–0·095, p<0·001). Over the whole 
12 month follow-up period it was 0·103 of a quality-adjusted 
life-year (0·025–0·182, p=0·01)
The average direct cost of the intervention including 
nurse time and psychiatrist supervision (but not the cost 
of nurse training or screening for depression), was 
£261·65 [US$523] per patient. Patients who received the 
intervention also had slightly greater costs  for health 
care than did those who had usual care (£175·33 vs 
£151·44, diﬀ erence £23·89) and for antidepressant drugs 
(£70·11 vs £20·79, diﬀ erence £49·32). The total average 
extra cost of the intervention was therefore £334·86 
[$670] (95% CI £276–£393) per patient over 6 months, 
which corresponds to £5278 [$10 556] per quality-adjusted 
life-year gained. A conservative sensitivity analysis, taking 
the lower limit of the 95% CI for the eﬀ ect size 
(0·032 QALYs) and the upper limit for the additional cost 
(£393) gives a cost of £12 300 per quality-adjusted life-year 
gained. Taking the upper limit for the eﬀ ect size 
(0·095 QALYs) and the lower limit for the additional 
cost (£276) gives a cost of £2900 per quality-adjusted 
life-year gained.
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Figure 2: Change in SCL-20 depression scale* over ﬁ rst 3 months
*Checklist of depressive symptoms.14 The mean for each group is shown in red.
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Figure 3: SCL-20 depression scale* at each timepoint
*Checklist of depressive symptoms.14 Boxes show the interquartile range (IQR), with continuous lines for median 
scores, and dotted lines for means. Whiskers indicate range. Dots beyond the whiskers are outliers, deﬁ ned as any 
point outside the IQR by any more than 1·5 times the IQR. 
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At 3 months, the only serious adverse events recorded 
were two cancer-related deaths in the group that had 
usual care plus the intervention. During the remaining 
9 months of follow-up, there were 11 cancer-related 
deaths and one death by suicide in the usual care group, 
and seven cancer-related deaths in the intervention 
group.
Discussion
For patients with major depressive disorder identiﬁ ed 
by screening who attended a cancer centre, supple-
mentation of usual care with a nurse-delivered complex 
intervention improved the symptoms of depression 
more than did usual care alone. The size of the treatment 
eﬀ ect that we recorded in both the self-rated and 
interview-based secondary outcomes at 3 months, and 
its persistence to 12 months support the clinical 
signiﬁ cance of this improvement in the primary 
outcome. We also noted evidence that the intervention 
caused an improvement in anxiety and fatigue, but not 
in pain or physical functioning, perhaps because anxiety 
and fatigue are more closely related to depression. 
Furthermore, the intervention proved to be feasible to 
deliver, acceptable to the patients who received it and 
also cost eﬀ ective in terms of the increase in 
quality-adjusted life-years achieved.
The complex intervention, Depression Care for People 
with Cancer, was designed to address the 
well-documented failings in the care of depressed 
patients who have comorbid medical disorders. The 
components were chosen because they have each been 
proven to be eﬀ ective for the treatment of depression; 
we did not therefore aim to assess them individually or 
to identify active ingredients. Rather, we aimed to assess 
whether the intervention was feasible, acceptable, and 
cost-eﬀ ective.
Since we wanted to know if we could improve on the 
usual care that such patients would receive, all patients 
received usual care. In the UK, usual care for this 
patient group includes both specialist cancer care and 
primary care. However, for ethical reasons, we optimised 
usual care by informing primary-care doctors whose 
patients were taking part in our study that these patients 
had major depressive disorder. Therefore, prescription 
of antidepressants was higher in both groups than we 
have previously reported for patients who receive usual 
care alone.5 Consequently the relative beneﬁ t of the 
intervention could have been even greater if the doctors 
who provided the usual care had not been informed of 
the diagnosis of major depressive disorder. Very few 
patients in either group were referred to specialist 
mental-health services.
A systematic review in 2006 concluded that there was 
little evidence to guide management of depressive 
disorder in patients with cancer.25 A pilot trial of a 
nurse-delivered complex intervention for patients with 
cancer was done in socially deprived Latin American 
women in the USA.26 Similar interventions for depression, 
in patients with other comorbidities have been trialled in 
primary care,17 including one in patients with coexisting 
diabetes mellitus,27 and one in elderly people who had 
various chronic diseases.21  We aimed to test such an 
intervention in cancer patients.
The ﬁ nding that the treatment eﬀ ect was sustained at 
12 months was surprising to us, since the intervention 
was very brief (consisting of 3 months of sessions and a 
further 3 months’ follow-up), and the patients had no 
monitoring or additional treatment in the second 
6 month period. Sustained treatment eﬀ ects have been 
reported in primary-care trials of similar interventions.28 
We might have recorded a bigger treatment eﬀ ect at 
12 months if we had continued to monitor, and intervened 
if patients relapsed after 6 months.
We chose to employ specially trained cancer nurses as 
care managers, supervised by psychiatrists. A systematic 
review of complex interventions for depression in 
Usual care group 
(N=99)
Usual care plus intervention 
group (N=97)
Eﬀ ect size p value
ANCOVA (mean diﬀ erence as eﬀ ect size)
SCL-20 depression score (0–4)* 1·54 (0·80) 1·25 (0·77) −0·34 (−0·55 to −0·13) 0·002
SCL-10 anxiety score (0–4)*† 0·97 (0·78)§ 0·78 (0·82)¶ −0·20 (−0·32 to −0·09) 0·0008
Pain score (0–100)‡ 37·8 (33·1)§ 36·8 (31·0)¶ −2·2 (−10·2 to 5·9) 0·597
Fatigue score (0–100)‡ 55·4 (27·6)§ 49·7 (27·1)¶ −9·4 (−15·5 to −3·4) 0·003
Physical functioning (0–100)‡ 67·6 (23·6)|| 66·8 (24·4)¶ 1·0 (−3·4 to 5·5) 0·643
Logistic regression (odds ratio as eﬀ ect size)
Treatment response (50% reduction on SCL-20)* 34 (34%) 51 (53%) 2·2 (1·2 to 4·0) 0·008
Remission of major depressive disorder (<0·75 on SCL-20)* 14 (14%) 28 (29%) 2·9 (1·4 to 6·3) 0·005
Remission of major depressive disorder (SCID)** 44 (45%)†† 65 (68%)‡‡ 3·0 (1·6 to 5·5) <0·001
Data are number (%), mean (SD), or diﬀ erence (95% CI). *Both subscales derived from Symptom Checklist-90.14 †To achieve a normal distribution for ANCOVA the scores for this 
measure were square root transformed; the treatment eﬀ ect cannot, therefore, be interpreted as actual scores. ‡European Organisation for Research and Treatment of Cancer 
quality of life questionnaire. §N=93. ¶N=91. ||N=92. **Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). ††N=98. ‡‡N=96.
Table 2: Comparison of outcomes at 3 months
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primary care concluded that the most eﬀ ective variants 
of this type of intervention had care managers with 
mental-health training who were supervised by 
psychiatrists.10 Our justiﬁ cation for training cancer 
nurses to deliver the intervention, rather than 
mental-health nurses, was to maximise acceptability to 
patients and integration with their existing medical 
care.
The incremental cost associated with the intervention 
was £334 (US$668) over 6 months. The cost per quality-
adjusted life-year gained, of £5278 ($10 556), was well 
within what is usually considered to be cost-eﬀ ective29 and 
compared with a median cost per quality-adjusted life-year 
of at least £10 000 ($20 000) for anticancer treatments. We 
did not include the one-oﬀ  cost of training the nurses, the 
cost of quality assurance and control procedures used in 
the trial, or the cost of the screening system used to identify 
patients with depression. However, even if these costs were 
included, the intervention would still probably be a 
relatively cheap and acceptable model for eﬀ ective 
treatment of comorbid depression in patients who attend 
medical services.
The ﬁ ndings of this trial need to be set in the context of 
potential limitations: the ﬁ rst is the validity of the diag-
nosis and measurement of major depression in medically 
ill patients. Although low mood and anhedonia are 
speciﬁ c to depression, the physical symptoms of 
depression can overlap with those caused by medical 
disorders. However, evidence suggests that this potential 
diﬃ  culty has been over estimated.30 Furthermore, all 
patients in our trial had the diagnosis of major depressive 
disorder conﬁ rmed at inter view and patients were also 
required to have a high symptom score on the SCL-20 
depression scale. Moreover, the two groups of patients 
had similar severity of cancer and associated physical 
symptoms, so that even if these symptoms did aﬀ ect the 
assessment of depression they were unlikely to have 
accounted for the diﬀ erence in outcomes.
A second limitation is the possibility of bias in the 
self-rated outcome assessments. Because of the type of 
trial, patients knew their treatment allocation. However, 
both the self-reported and independently assessed results 
were similar.
Third is the question of generalisability of the 
ﬁ ndings. We excluded patients who had cancers with 
poor prognoses and patients who had treatment needs 
that we considered could be more appropriately met by 
readily available specialist psychiatric services (such as 
chronic depression, that antedated the diagnosis of 
cancer). About 40% of eligible patients declined to take 
part—a rate of participation which is similar to that in 
other trials which have recruited depressed patients by 
screening those attending specialist medical services.31 
However, most of these patients refused to be assessed 
for eligibility; very few withdrew after the interview. We 
do not know if as many patients would refuse the 
intervention outside a trial setting, or whether a better 
explanation at an early stage of recruitment might 
reduce the number of refusals. We did the trial at only 
one major cancer centre, and in the UK NHS, where all 
patients are registered with a primary-care doctor and 
have free access to specialist services including 
psychiatry. Since the UK NHS is not typical of all health 
services, implementation of this approach in other 
health care systems might necessitate adaptations such 
as having the antidepressant medication prescribed by 
the oncologist, and including patients with more 
complex needs such as chronic depression and 
substance misuse.
This initial proof-of-concept trial raises many questions. 
In further trials (SMaRT oncology 2 and 3), we aim to 
investigate whether Depression Care for People with 
Cancer is cost eﬀ ective if implemented on a large scale 
and if screening, training of nurses, and other costs are 
fully assessed and whether this intervention can also 
beneﬁ t patients who have cancers with poor prognoses, 
such as lung cancer. Other questions still to be addressed 
are whether the beneﬁ t for quality of life would improve 
if other symptoms, such as pain, were treated at the same 
time;32 and whether this approach is eﬀ ective for patients 
who attend specialist services for other medical disorders 
or for patients being treated in other health care systems. 
This proof-of-concept trial provides preliminary evidence 
that such a system of delivering care for depressed 
patients who attend specialist medical services such as 
cancer centres oﬀ ers a feasible, acceptable, and cost-
eﬀ ective way to improve patients’ quality of life.
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